MAX HEALTHCARE, APOLLO HOSPITALS RALLY UP TO 4.5%
MAXHEALTH Max Healthcare and Apollo Hospitals surged up to 4.5% on November 20, emerging among the top gainers on the Nifty 50 after global brokerage Macquarie upgraded both healthcare stocks to 'Outperform' from its earlier ratings. Consensus earnings estimates have bottomed out and valuations have become more attractive. The brokerage also noted that the initial profitability pressure arising from the ongoing bed expansion cycle is already factored into stock prices, while newly added hospital capacity is ramping up at a healthy pace. Following the upgrade, Max Healthcare shares climbed 3.5% apiece, while Apollo Hospitals advanced 4.5%. Macquarie raised its target price for Max Healthcare to Rs 1,450 and Apollo Hospitals to Rs 10,500. The brokerage also highlighted that Max Healthcare offers a relatively better risk-reward opportunity between the two stocks. Meanwhile, concerns over the earnings impact of price caps on oncology drugs appear to be easing. Deepika Muraka, healthcare sector analyst at Choice Equity Broking, told Informist that hospitals could offset some of the impact by increasing prices of other services. Earlier estimates suggested that the price caps could reduce earnings before interest, tax, depreciation and amortisation by around 7%. However, if healthcare companies raise prices across other services to compensate for the impact, the expected hit could decline significantly to around 2%. The improving outlook for hospital profitability, ongoing capacity expansion and favourable brokerage commentary have supported investor sentiment towards Max Healthcare and Apollo Hospitals.



















